Forte Biosciences (FBRX) Research & Development (2016 - 2026)
Forte Biosciences (FBRX) reported Research & Development of $20.3 million for Q1 2026, up 62.02% year-over-year from $12.5 million in Q1 2025, and down 5.86% quarter-over-quarter from $21.6 million in Q4 2025.
Forte Biosciences (FBRX) Research & Development (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has 11 years of Research & Development data on file, last reported at $20.3 million in Q1 2026.
- Research & Development for Q1 2026 came in at $20.3 million, up 62.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $65.4 million (up 126.13% YoY), and the FY2025 annual result was $57.6 million, up 178.3% from the prior year.
- Research & Development fell to $20.3 million in Q1 2026 per FBRX's latest filing, from $21.6 million in the prior quarter.
- Over five years, Research & Development peaked at $21.6 million in Q4 2025 and troughed at $693000.0 in Q1 2022.
- A 5-year average of $7.4 million and a median of $5.6 million in 2024 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2023: Research & Development slumped 79.14% in 2022, then soared 590.76% in 2023.
- A 5-year view of Research & Development shows it stood at $2.5 million in 2022, then surged by 43.37% to $3.6 million in 2023, then surged by 42.42% to $5.1 million in 2024, then jumped by 324.92% to $21.6 million in 2025, then decreased by 5.86% to $20.3 million in 2026.
- Business Quant data shows FBRX's Research & Development at $20.3 million in Q1 2026, $21.6 million in Q4 2025, and $15.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -2.30 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 1.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -58.00 Mn |
| 10 | Forte Biosciences | 70.77 Mn | 12.55 Mn | - | 20.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.32 Mn |
| Dec 31, 2025 | 21.59 Mn |
| Sep 30, 2025 | 15.05 Mn |
| Jun 30, 2025 | 8.47 Mn |
| Mar 31, 2025 | 12.54 Mn |
| Dec 31, 2024 | 5.08 Mn |
| Sep 30, 2024 | 5.72 Mn |
| Jun 30, 2024 | 5.59 Mn |
| Mar 31, 2024 | 4.32 Mn |
| Dec 31, 2023 | 3.57 Mn |
| Sep 30, 2023 | 6.37 Mn |
| Jun 30, 2023 | 7.14 Mn |
| Mar 31, 2023 | 4.79 Mn |
| Dec 31, 2022 | 2.49 Mn |
| Sep 30, 2022 | 1.38 Mn |
| Jun 30, 2022 | 1.03 Mn |
| Mar 31, 2022 | 693,000.00 |
| Dec 31, 2021 | 1.35 Mn |
| Sep 30, 2021 | 5.66 Mn |
| Jun 30, 2021 | 3.52 Mn |